Our Science
At MOTE, we innovate in targeted delivery. Our non-covalent surface functionalization technology enables scalable and modular targeting of a wide range of cell types.
Our mobilize TM Platform
Our core platform technology focuses on developing proprietary targeted LNPs (tLNPS) through a modular, simple and elegant process that circumvents the challenges associated with the conventional chemical surface functionalization approaches. A simple inline mixing allows tethering of a recombinant targeting ligand that posstmarks the RNA containing LNPs to specific target tissues for a precision in vivo cell reprogramming.
Our Pipeline
We are building a portfolio of targeted RNA nanomedicines to address unmet medical needs in several therapeutic areas, including immune cell reprogramming, as well as treatments targeting CNS tissues and hematopoietic stem cells (HSCs).
| Target | Indication | Discovery | Preclinical | Phase l |
|---|---|---|---|---|
| T Cells | Systemic Lupus Erythematosus | |||
| HSC | TBD | |||
| CNS | TBD |








About Us
MOTE Therapeutics is an innovative preclinical-stage startup building the RNA medicines of tomorrow.
A Next-Gen RNA Delivery
Platform
MOTE Therapeutics is an innovative biotechnology startup. We are building the leading platform for targeted RNA delivery — unlocking new classes of therapeutics for tissues and cell types previously beyond reach.
mobilize, a noncovalent
functionalization platform
MOTE has developed a targeted LNP platform named mobilize for extrahepatic delivery of circRNA. The platform combines hepatic de - targeting with cell - specific ligand engineering.
Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch Get in Touch
Have questions about our science or want to learn more about MOTE?
Please fill out the form in the link below to get in contact.
Get in Touch Today
Reach us by filling the form below for any inquiries or support.